Article
Differences in gynecologic tumor development in Amhr2-Cre mice with KRASG12D or KRASG12V mutations.
Scientific reports - 26 Nov 2020
Kun Eucharist H S, Tsang Yvonne T M, Lin Sophia, Pan Sophia, Medapalli Tejas, Malpica Anais, Richards JoAnne S, Gershenson David M, Wong Kwong-Kwok
Abstract excerpt
How different KRAS variants impact tumor initiation and progression in vivo has not been thoroughly examined. We hypothesize that the ability of either KRASG12D or KRASG12V mutations to initiate tumor formation is context dependent. Amhr2-Cre mice express Cre recombinase in tissues that develop into the fallopian tubes, uterus, and ovaries. We used these mice to conditionally express either the KRASG12V/+ or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.